AC-262536

AC-262536 is a selective and non-steroidal androgen receptor modulators ( SARMs ) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen receptor , with an affinity in the low nanomolar range (1-10 nM). In Vitro AC-262536 dose-dependently inhibits dihydroxytestosterone (DHT)-induced proliferation of LNCaP. The effects are significant with 100 nM AC-262536 (%inhibition 47.2±12.2), and reaches a plateau with 1 μM treatment (%inhibition 50.7±7.6). Thus, AC-262536 can act as a functional antagonist in prostate cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo AC-262536 (3, 10, 30 mg/kg) reverses the luteinizing hormone (LH) spike in castrated rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (200-225 g) Dosage: 3, 10 and 30 mg/kg Administration: Administered subcutaneously; once daily for 14 consecutive days Result: Significantly decreased LH levels by about 40% at the 3 mg/kg dose. The ED 50 was determined to be 2.8 mg/kg. At the 10 and 30 mg/kg doses, the effects of AC-262536 were significantly stronger than Testosterone Propionate (TP) : 1.91±0.32 ng/mL and 1.53±0.34 ng/mL vs. 3.12±0.69 ng/mL, respectively.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet